Cargando…

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

BACKGROUND: Post treatment minimal residual disease (MRD) determination contributes to impending relapse prediction, chemotherapy response and clinical outcomes assessment, guiding clinicians to develop reasonable and effective individual chemotherapy options after induction/consolidation. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Ju, He, Aili, Zhang, Wanggang, Huang, Chen, Yang, Juan, Yang, Yun, Wang, Jianli, Zhang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751134/ https://www.ncbi.nlm.nih.gov/pubmed/23915341 http://dx.doi.org/10.1186/1477-5956-11-39

Ejemplares similares

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2014)

Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2020)

Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia
por: SONG, WEI, et al.
Publicado: (2013)

Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma
por: Bai, Ju, et al.
Publicado: (2019)

Serum Peptidomic Profile as a Novel Biomarker for Rheumatoid Arthritis
por: Abdelati, Abeer A., et al.
Publicado: (2020)

Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technology
por: Zhang, Yang, et al.
Publicado: (2017)

Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics
por: Feng, Yuandong, et al.
Publicado: (2018)

Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study
por: Ma, Xiaorong, et al.
Publicado: (2016)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia
por: Zhao, Shenglong, et al.
Publicado: (2022)

C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia
por: Lei, Bo, et al.
Publicado: (2017)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia
por: Wen, Qiaojun, et al.
Publicado: (2013)

Analysis of the Yeast Peptidome and Comparison with the Human Peptidome
por: Dasgupta, Sayani, et al.
Publicado: (2016)

Influence of Honeybee Sting on Peptidome Profile in Human Serum
por: Matysiak, Jan, et al.
Publicado: (2015)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
por: Alizad Ghandforoush, Nasrin, et al.
Publicado: (2016)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
por: Mosna, Federico, et al.
Publicado: (2017)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Minimal Information About an Immuno‐Peptidomics Experiment (MIAIPE)
por: Lill, Jennie R., et al.
Publicado: (2018)

MALDI‐TOF‐MS analysis in low molecular weight serum peptidome biomarkers for NSCLC
por: Song, Yufan, et al.
Publicado: (2022)

Serum peptidome profiles immune response of COVID-19 Vaccine administration
por: Zhang, Wenjia, et al.
Publicado: (2022)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
por: Chen, Xiaoyan, et al.
Publicado: (2021)

The Process Chain for Peptidomic Biomarker Discovery
por: Schrader, Michael, et al.
Publicado: (2006)

Urinary Peptidomic Biomarkers in Kidney Diseases
por: Sirolli, Vittorio, et al.
Publicado: (2019)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
por: Levine, Ross L., et al.
Publicado: (2019)

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
por: Hirsch, Pierre, et al.
Publicado: (2017)

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia
por: Bacher, Ulrike, et al.
Publicado: (2011)

Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling
por: OKANO, TETSUYA, et al.
Publicado: (2016)

Urinary peptidomic biomarkers of renal function in heart transplant recipients
por: Huang, Qi-Fang, et al.
Publicado: (2019)

Long non-coding RNA RPPH1 promotes the proliferation, invasion and migration of human acute myeloid leukemia cells through down-regulating miR-330-5p expression
por: Lei, Bo, et al.
Publicado: (2019)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

Magnetic Bead-Based Serum Peptidome Profiling in Patients with Gestational Diabetes Mellitus
por: Ai, Tingting, et al.
Publicado: (2015)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease
por: Helbig, Daniel, et al.
Publicado: (2020)

Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia
por: Moffitt, Andrea B, et al.
Publicado: (2020)

UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia
por: Weijler, Lisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n4deb97immh8hin5gqgt6nvrbq